 |
|
|
| |
Switching to bictegravir/emtricitabine/tenofovir
alafenamide (B/F/TAF) in adults aged 65 years or older:
week 96 results from an international, Phase 3b, open-label trial
|
| |
| |
IAS 2021 July 18-21
Franco MaggioloAuthors:F. Maggiolo * (1), G. Rizzardini (2), J.-M. Molina (3), F. Pulido (4), S. De Wit (5), L. Vandekerckhove (6), J. Berenguer (7), M. D'Antoni (8), C. Blair (8), S. Chuck (8), H. Martin (8), I. McNicholl (8), R. Haubrich (8), J. Gallant (8)Institutions:(1) Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, (2) Division of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, (3) Saint Louis Hospital, University Paris Diderot, Department of Infectious Diseases, Paris, France, (4) Unidad VIH, Hospital Universitario 12 de Octubre, imas12, UCM, Madrid, Spain, (5) St Pierre University Hospital, Universite Libre de Bruxelles, Brussels, Belgium, (6) University Hospital, Ghent, Belgium, (7) Infectious Diseases, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain, (8) Gilead Sciences, Foster City, United States
|
| |
|
|
|
|
|
